Enveric Biosciences, Inc. Logo

Enveric Biosciences, Inc.

ENVB

(1.2)
Stock Price

0,49 USD

-437.55% ROA

-344.02% ROE

-0.1x PER

Market Cap.

2.904.423,00 USD

0% DER

0% Yield

0% NPM

Enveric Biosciences, Inc. Stock Analysis

Enveric Biosciences, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Enveric Biosciences, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.65x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

3 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

4 ROE

Negative ROE (-184.47%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-256.14%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Enveric Biosciences, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Enveric Biosciences, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Enveric Biosciences, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Enveric Biosciences, Inc. Revenue
Year Revenue Growth
1994 200.000
1995 1.200.000 83.33%
1996 2.024.187 40.72%
1997 2.781.233 27.22%
1998 1.679.715 -65.58%
1999 1.660.371 -1.17%
2000 2.201.812 24.59%
2001 1.603.782 -37.29%
2002 1.855.934 13.59%
2003 1.269.286 -46.22%
2004 1.105.923 -14.77%
2005 1.192.447 7.26%
2006 333.201 -257.88%
2007 750.706 55.61%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 15.976.422 100%
2016 36.145.589 55.8%
2017 48.593.712 25.62%
2018 42.998.280 -13.01%
2019 39.914.675 -7.73%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Enveric Biosciences, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1994 0
1995 0 0%
1996 2.540.084 100%
1997 3.707.995 31.5%
1998 755.899 -390.54%
1999 383.176 -97.27%
2000 540.269 29.08%
2001 639.223 15.48%
2002 432.826 -47.69%
2003 458.940 5.69%
2004 393.004 -16.78%
2005 354.138 -10.97%
2006 157.739 -124.51%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 174.083 100%
2021 4.788.807 96.36%
2022 8.027.773 40.35%
2023 5.407.000 -48.47%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Enveric Biosciences, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1994 0
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 811.024 100%
2004 0 0%
2005 0 0%
2006 0 0%
2007 433.667 100%
2008 0 0%
2009 0 0%
2010 35.875 100%
2011 31.395 -14.27%
2012 22.690 -38.36%
2013 27.211 16.61%
2014 32.811 17.07%
2015 5.687.913 99.42%
2016 8.552.966 33.5%
2017 0 0%
2018 0 0%
2019 0 0%
2020 5.443.234 100%
2021 20.499.052 73.45%
2022 11.605.761 -76.63%
2023 8.041.396 -44.33%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Enveric Biosciences, Inc. EBITDA
Year EBITDA Growth
1994 -1.100.000
1995 -3.400.000 67.65%
1996 -25.073.690 86.44%
1997 -4.270.224 -487.18%
1998 -1.766.929 -141.67%
1999 554.315 418.76%
2000 440.963 -25.71%
2001 -219.332 301.05%
2002 119.706 283.23%
2003 -400.883 129.86%
2004 -92.920 -331.43%
2005 -42.919 -116.5%
2006 -317.563 86.48%
2007 -261.307 -21.53%
2008 -151.441 -72.55%
2009 -55.569 -172.53%
2010 -35.875 -54.9%
2011 -31.395 -14.27%
2012 -22.690 -38.36%
2013 -27.211 16.61%
2014 -32.811 17.07%
2015 33.156 198.96%
2016 -2.827.771 101.17%
2017 -7.193.222 60.69%
2018 -1.723.157 -317.44%
2019 -4.055.057 57.51%
2020 -6.419.426 36.83%
2021 -26.388.181 75.67%
2022 -19.526.243 -35.14%
2023 -10.961.112 -78.14%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Enveric Biosciences, Inc. Gross Profit
Year Gross Profit Growth
1994 200.000
1995 1.200.000 83.33%
1996 1.838.647 34.73%
1997 2.551.497 27.94%
1998 1.545.525 -65.09%
1999 1.611.591 4.1%
2000 2.039.564 20.98%
2001 1.506.999 -35.34%
2002 1.725.418 12.66%
2003 1.146.869 -50.45%
2004 994.528 -15.32%
2005 1.086.385 8.46%
2006 332.304 -226.93%
2007 687.437 51.66%
2008 0 0%
2009 0 0%
2010 0 0%
2011 -31.395 100%
2012 -22.690 -38.36%
2013 0 0%
2014 0 0%
2015 5.750.998 100%
2016 6.536.657 12.02%
2017 10.237.745 36.15%
2018 8.983.504 -13.96%
2019 8.150.720 -10.22%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Enveric Biosciences, Inc. Net Profit
Year Net Profit Growth
1994 -1.200.000
1995 -3.200.000 62.5%
1996 -25.395.170 87.4%
1997 -4.719.821 -438.05%
1998 -5.792.061 18.51%
1999 354.792 1732.52%
2000 382.019 7.13%
2001 -240.107 259.1%
2002 18.292 1412.63%
2003 -495.453 103.69%
2004 -157.490 -214.59%
2005 -81.515 -93.2%
2006 -352.626 76.88%
2007 807.276 143.68%
2008 -143.636 662.03%
2009 -58.544 -145.35%
2010 -39.441 -48.43%
2011 -33.380 -18.16%
2012 -24.621 -35.58%
2013 -161 -15192.55%
2014 -33.644 99.52%
2015 -1.890.758 98.22%
2016 -2.780.686 32%
2017 -9.074.813 69.36%
2018 -16.897.516 46.29%
2019 -5.603.975 -201.53%
2020 -6.386.945 12.26%
2021 -48.976.896 86.96%
2022 -18.471.333 -165.15%
2023 -11.288.864 -63.62%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Enveric Biosciences, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1994 -70.588
1995 -168.421 58.09%
1996 -1.209.294 86.07%
1997 -196.659 -514.92%
1998 -186.841 -5.26%
1999 6.823 2838.79%
2000 7.208 5.34%
2001 -4.530 259.09%
2002 345 1413.04%
2003 -9.348 103.69%
2004 -2.972 -214.64%
2005 -1.482 -100.47%
2006 -6.411 76.88%
2007 11.059 157.98%
2008 -1.968 662.18%
2009 -802 -145.57%
2010 -540 -48.33%
2011 -244 -122.22%
2012 -180 -35.75%
2013 -1 -17800%
2014 -192 99.48%
2015 -852 77.44%
2016 -1.064 20.02%
2017 -3.029 64.86%
2018 -3.551 14.73%
2019 -526 -575.1%
2020 -56 -856.36%
2021 -104 46.6%
2022 -13 -758.33%
2023 -5 -140%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Enveric Biosciences, Inc. Free Cashflow
Year Free Cashflow Growth
1994 -900.000
1995 -3.800.000 76.32%
1996 -5.008.373 24.13%
1997 -4.121.986 -21.5%
1998 -3.074.237 -34.08%
1999 -688.487 -346.52%
2000 105.355 753.49%
2001 -359.986 129.27%
2002 10.145 3648.41%
2003 -255.736 103.97%
2004 339.932 175.23%
2005 -261.845 229.82%
2006 -320.920 18.41%
2007 329.928 197.27%
2008 -150.186 319.68%
2009 -65.041 -130.91%
2010 -40.666 -59.94%
2011 -30.346 -34.01%
2012 -24.850 -22.12%
2013 -21.632 -14.88%
2014 -43.164 49.88%
2015 -5.357.706 99.19%
2016 -6.392.985 16.19%
2017 -2.745.634 -132.84%
2018 -2.565.495 -7.02%
2019 -2.537.454 -1.11%
2020 -3.932.928 35.48%
2021 -12.322.390 68.08%
2022 -17.730.888 30.5%
2023 -2.740.441 -547.01%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Enveric Biosciences, Inc. Operating Cashflow
Year Operating Cashflow Growth
1994 -800.000
1995 -3.600.000 77.78%
1996 -4.724.535 23.8%
1997 -3.697.465 -27.78%
1998 -2.996.808 -23.38%
1999 -665.382 -350.39%
2000 145.844 556.23%
2001 -339.675 142.94%
2002 85.138 498.97%
2003 -253.965 133.52%
2004 343.939 173.84%
2005 -256.568 234.05%
2006 -305.907 16.13%
2007 329.928 192.72%
2008 -150.186 319.68%
2009 -65.041 -130.91%
2010 -40.666 -59.94%
2011 -30.346 -34.01%
2012 -24.850 -22.12%
2013 -21.632 -14.88%
2014 -43.164 49.88%
2015 -3.671.622 98.82%
2016 -2.703.989 -35.79%
2017 -2.740.794 1.34%
2018 -2.565.495 -6.83%
2019 -2.453.123 -4.58%
2020 -3.888.785 36.92%
2021 -11.457.671 66.06%
2022 -17.146.723 33.18%
2023 -2.740.433 -525.69%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Enveric Biosciences, Inc. Capital Expenditure
Year Capital Expenditure Growth
1994 100.000
1995 200.000 50%
1996 283.838 29.54%
1997 424.521 33.14%
1998 77.429 -448.27%
1999 23.105 -235.12%
2000 40.489 42.94%
2001 20.311 -99.35%
2002 74.993 72.92%
2003 1.771 -4134.5%
2004 4.007 55.8%
2005 5.277 24.07%
2006 15.013 64.85%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 1.686.084 100%
2016 3.688.996 54.29%
2017 4.840 -76118.93%
2018 0 0%
2019 84.331 100%
2020 44.143 -91.04%
2021 864.719 94.9%
2022 584.165 -48.03%
2023 8 -7301962.5%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Enveric Biosciences, Inc. Equity
Year Equity Growth
1994 1.400.000
1995 3.700.000 62.16%
1996 3.267.873 -13.22%
1997 1.525.113 -114.27%
1998 -1.553.490 198.17%
1999 768.137 302.24%
2000 1.650.675 53.47%
2001 1.411.568 -16.94%
2002 1.428.832 1.21%
2003 955.379 -49.56%
2004 797.735 -19.76%
2005 717.402 -11.2%
2006 376.501 -90.54%
2007 1.557.105 75.82%
2008 48.469 -3112.58%
2009 -10.075 581.08%
2010 -49.516 79.65%
2011 4.555 1187.07%
2012 -20.066 122.7%
2013 -20.227 0.8%
2014 -3.871 -422.53%
2015 258.533 101.5%
2016 11.660.321 97.78%
2017 19.444.801 40.03%
2018 10.759.097 -80.73%
2019 10.621.547 -1.3%
2020 3.415.641 -210.97%
2021 22.305.920 84.69%
2022 15.556.952 -43.38%
2023 2.435.646 -538.72%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Enveric Biosciences, Inc. Assets
Year Assets Growth
1994 2.300.000
1995 4.400.000 47.73%
1996 4.141.195 -6.25%
1997 3.165.114 -30.84%
1998 893.451 -254.26%
1999 2.117.999 57.82%
2000 2.457.024 13.8%
2001 1.753.106 -40.15%
2002 1.745.840 -0.42%
2003 1.205.145 -44.87%
2004 1.464.044 17.68%
2005 896.921 -63.23%
2006 463.576 -93.48%
2007 1.605.008 71.12%
2008 69.675 -2203.56%
2009 1.792 -3788.11%
2010 1.126 -59.15%
2011 22.450 94.98%
2012 5.600 -300.89%
2013 4.468 -25.34%
2014 5.085 12.13%
2015 13.834.934 99.96%
2016 39.507.923 64.98%
2017 52.196.628 24.31%
2018 29.637.450 -76.12%
2019 25.005.152 -18.53%
2020 4.096.891 -510.34%
2021 26.719.133 84.67%
2022 19.552.925 -36.65%
2023 6.619.194 -195.4%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Enveric Biosciences, Inc. Liabilities
Year Liabilities Growth
1994 900.000
1995 700.000 -28.57%
1996 873.322 19.85%
1997 1.640.001 46.75%
1998 2.446.941 32.98%
1999 1.349.862 -81.27%
2000 806.349 -67.4%
2001 341.538 -136.09%
2002 317.008 -7.74%
2003 249.766 -26.92%
2004 666.309 62.51%
2005 179.519 -271.16%
2006 87.075 -106.17%
2007 47.903 -81.77%
2008 21.206 -125.89%
2009 11.867 -78.7%
2010 50.642 76.57%
2011 17.895 -183%
2012 25.666 30.28%
2013 24.695 -3.93%
2014 8.956 -175.74%
2015 13.576.401 99.93%
2016 27.844.220 51.24%
2017 32.748.445 14.98%
2018 18.878.353 -73.47%
2019 14.383.605 -31.25%
2020 681.250 -2011.35%
2021 4.413.213 84.56%
2022 3.995.973 -10.44%
2023 4.183.548 4.48%

Enveric Biosciences, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-12.87
Price to Earning Ratio
-0.1x
Price To Sales Ratio
0x
POCF Ratio
-0.17
PFCF Ratio
-0.18
Price to Book Ratio
1.11
EV to Sales
0
EV Over EBITDA
0.08
EV to Operating CashFlow
0.09
EV to FreeCashFlow
0.09
Earnings Yield
-10.28
FreeCashFlow Yield
-5.45
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
18.05
Graham NetNet
0.04

Income Statement Metrics

Net Income per Share
-12.87
Income Quality
0.7
ROE
-3.44
Return On Assets
-4.21
Return On Capital Employed
-10.81
Net Income per EBT
1.16
EBT Per Ebit
0.91
Ebit per Revenue
0
Effective Tax Rate
-0.18

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-7.3
Free CashFlow per Share
-7.31
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
-0.03
Return on Invested Capital
-12.8
Return on Tangible Assets
-4.38
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
-0.01

Balance Sheet

Cash per Share
1,97
Book Value per Share
1,13
Tangible Book Value per Share
1.01
Shareholders Equity per Share
1.13
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.25
Current Ratio
1.39
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.04
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Enveric Biosciences, Inc. Dividends
Year Dividends Growth
2008 4

Enveric Biosciences, Inc. Profile

About Enveric Biosciences, Inc.

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

CEO
Dr. Joseph Edward Tucker Ph.D.
Employee
25
Address
4851 Tamiami Trail North
Naples, 34103

Enveric Biosciences, Inc. Executives & BODs

Enveric Biosciences, Inc. Executives & BODs
# Name Age
1 Dr. Joseph Edward Tucker Ph.D.
Chief Executive Officer & Director
70
2 Dr. Peter J. Facchini Ph.D.
Chief Innovation Officer
70
3 Mr. Kevin M. Coveney CPA
Chief Financial Officer
70

Enveric Biosciences, Inc. Competitors